ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

ClinicalTrials.gov ID: NCT02600494

Public ClinicalTrials.gov record NCT02600494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression)

Study identification

NCT ID
NCT02600494
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Enrollment
554 participants

Conditions and interventions

Interventions

  • ITI-007 (Lumateperone) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2015
Primary completion
Jan 27, 2019
Completion
Jul 23, 2019
Last update posted
Nov 2, 2025

2015 – 2019

United States locations

U.S. sites
55
U.S. states
20
U.S. cities
55
Facility City State ZIP Site status
Clinical Site Little Rock Arkansas
Clinical Site Rogers Arkansas
Clinical Site Cerritos California
Clinical Site Culver City California
Clinical Site Garden Grove California
Clinical Site Lemon Grove California
Clinical Site National City California
Clinical Site Oakland California
Clinical Site Oceanside California
Clinical Site Orange California
Clinical Site Pico Rivera California
Clinical Site Riverside California
Clinical Site San Diego California
Clinical Site San Marcos California
Clinical Site Santa Rosa California
Clinical Site Colorado Springs Colorado
Clinical Site Bradenton Florida
Clinical Site Fort Myers Florida
Clinical Site Jacksonville Florida
Clinical Site Lauderhill Florida
Clinical Site Miami Florida
Clinical Site North Miami Florida
Clinical Site Orlando Florida
Clinical Site Atlanta Georgia
Clinical Site Chicago Illinois
Clinical Site Hoffman Estates Illinois
Clinical Site Lake Charles Louisiana
Clinical Site Baltimore Maryland
Clinical Site Boston Massachusetts
Clinical Site O'Fallon Missouri
Clinical Site St Louis Missouri
Clinical Site Las Vegas Nevada
Clinical Site Berlin New Jersey
Clinical Site Cherry Hill New Jersey
Clinical Site Marlton New Jersey
Clinical Site Toms River New Jersey
Clinical Site Brooklyn New York
Clinical Site Cedarhurst New York
Clinical Site New York New York
Clinical Site Rochester New York
Clinical Site Staten Island New York
Clinical Site Cincinnati Ohio
Clinical Site Cleveland Ohio
Clinical Site Dayton Ohio
Clinical Site Garfield Heights Ohio
Clinical Site Oklahoma City Oklahoma
Clinical Site Allentown Pennsylvania
Clinical Site Norristown Pennsylvania
Clinical Site Philadelphia Pennsylvania
Clinical Site Memphis Tennessee
Clinical Site Austin Texas
Clinical Site Dallas Texas
Clinical Site Houston Texas
Clinical Site Petersburg Virginia
Clinical Site Everett Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02600494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02600494 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →